ArticleVeterinary world2025
One Health serosurveillance of anti-SARS-CoV-2 antibodies in domestic animals from the metropolitan area of Panama.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has raised concern regarding anthropozoonotic transmission to domestic animals, posing potential public and veterinary health risks. Latin America remains underrepresented in seroepidemiological assessments of such zoonotic spillover. This study aimed to detect anti-SARS-CoV-2 antibodies in domestic dogs and cats in Panama using a One Health surveillance framework. Materials and Methods: A cross-sectional serological survey was conducted between October 2022 and December 2023 across the metropolitan area of Panama City. Serum samples from 341 animals (198 dogs and 143 cats) were analyzed using a commercial double-antigen enzyme-linked immunosorbent assay to detect antibodies targeting the SARS-CoV-2 nucleocapsid protein. A historical panel of 100 pre-pandemic canine and feline samples was also tested. Demographic, clinical, and exposure data were collected through owner questionnaires, and statistical associations with seropositivity were assessed using univariate tests and binary logistic regression. Results: Seropositivity was detected in 12/341 animals (3.5%; 95% confidence interval: 1.96-6.11%), comprising 9 dogs (4.5%) and 3 cats (2.1%). In addition, 2/100 pre-pandemic canine samples (2.0%) tested positive. Most seropositive animals (75%) were reported to have lived in households with confirmed COVID-19 cases, although this variable was not statistically associated with seropositivity. Regression analysis identified ideal body condition as a significant predictor (p = 0.016), while sampling location and demographic variables were not significant. Conclusion: This study presents the first serological evidence of SARS-CoV-2 exposure in domestic pets in Panama. While low in prevalence, the findings underscore the relevance of community-based animal surveillance and reveal possible serological cross-reactivity with endemic canine coronaviruses. The data support the continued integration of domestic animal monitoring into One Health strategies to preempt zoonotic risks and improve pandemic preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.